Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RET M918T
i
Other names:
RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5979
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
cabozantinib capsule
Sensitive
:
A2
cabozantinib capsule
Sensitive: A2 - Guideline
cabozantinib capsule
Sensitive
:
A2
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C3 – Early Trials
pralsetinib
Sensitive
:
C3
pralsetinib
Sensitive: C3 – Early Trials
pralsetinib
Sensitive
:
C3
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: C3 – Early Trials
selpercatinib
Sensitive
:
C3
selpercatinib
Sensitive: C3 – Early Trials
selpercatinib
Sensitive
:
C3
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
sunitinib
Sensitive: C4 – Case Studies
sunitinib
Sensitive
:
C4
sunitinib
Sensitive: C4 – Case Studies
sunitinib
Sensitive
:
C4
RET M918T
Thyroid Gland Carcinoma
RET M918T
Thyroid Gland Carcinoma
XMD15-44
Sensitive: D – Preclinical
XMD15-44
Sensitive
:
D
XMD15-44
Sensitive: D – Preclinical
XMD15-44
Sensitive
:
D
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
AMG 706
Resistant: D – Preclinical
AMG 706
Resistant
:
D
AMG 706
Resistant: D – Preclinical
AMG 706
Resistant
:
D
RET M918T
Thyroid Gland Carcinoma
RET M918T
Thyroid Gland Carcinoma
HG-6-63-01
Sensitive: D – Preclinical
HG-6-63-01
Sensitive
:
D
HG-6-63-01
Sensitive: D – Preclinical
HG-6-63-01
Sensitive
:
D
RET M918T
Thyroid Gland Papillary Carcinoma
RET M918T
Thyroid Gland Papillary Carcinoma
AZD1480
Sensitive: D – Preclinical
AZD1480
Sensitive
:
D
AZD1480
Sensitive: D – Preclinical
AZD1480
Sensitive
:
D
RET M918T
Thyroid Gland Carcinoma
RET M918T
Thyroid Gland Carcinoma
ALW-II-41-27
Sensitive: D – Preclinical
ALW-II-41-27
Sensitive
:
D
ALW-II-41-27
Sensitive: D – Preclinical
ALW-II-41-27
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.